Miami Beach, Florida Jun 29, 2020 (Issuewire.com) - Consortium International Holdings, LLC (CIH), a Florida based company is happy to announce that pursuant to Section 564 of the Federal Food, Drug and Cosmetic Act, the Healgen Scientific Covid-19 IgG/IgM Rapid Test Cassette will be made available to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA, 42 U.S. C. 263a.), to perform moderate or high complexity tests throughout the United States.
Over the past months, Consortium International Holdings, LLC (CIH), has moved forward with the establishment of marketing and sales channels for the Healgen Covid-19 IgG/IgM Rapid Test Cassette in a number of countries throughout Central and South America, Africa and shortly into the Middle East and lower Asian. With the issuance of the Emergency Use Authorization for the Healgen Covid-19 IgG/IgM Rapid Test Cassette by the US FDA, Consortium will further expand its’ market and distribution penetration, serving the needs of those qualified laboratories within the United States and internationally.
According to Lawrence Salvo, Managing Member of Consortium International Holdings, LLC, “We are proud to be an active part of the marketing and sales team for the Healgen Covid-19 IgG/IgM Rapid Test Cassette and have been impressed by its performance in the detection of both IgM and IgG Antibodies for Covid-19 and its resulting high Sensitivity and Specificity.” Salvo further stated, “Repeatability of performance is essential in a rapid test and the Healgen Covid-19 IgG/IgM Rapid Test Cassette delivers consistent results which have been demonstrated through third-party evaluations to meet or exceed the performance of even our best competitors.”
CIH invites all inquiries and will respond within 24 hours. Please contact us at info@consortiummiami.com.
<END>
About Consortium International Holdings, LLC
Consortium International Holdings, LLC (CIH), is a rapidly growing Florida based distribution company that is involved in the international as well as the domestic distribution of diagnostics targeting primary as well as orphan infectious diseases.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results.
#####
Media Contact
1952 italpisces@gmail.com 3059784590 450 Alton Road, 3704 http://www.consortiummiami.com
